Evidence map›Paper›PMID 42385300›Full record

ArticleMolecular pharmacology2026

Molecular pharmacology of mGlu

Anthony S Ferranti, Youhyun Noh, Xia Lei, Xin Lin, Joseph D Bungard, Wesley B Asher, Jonathan A Javitch, Colleen M Niswender

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anthony S FerrantiDepartment of Pharmacology, Vanderbilt University, Nashville, Tennessee; Warren Center for Neuroscience Drug Discovery and Vanderbilt Institute for Translational Advances, Nashville, Tennessee.
Youhyun NohDepartment of Pharmacology, Vanderbilt University, Nashville, Tennessee; Warren Center for Neuroscience Drug Discovery and Vanderbilt Institute for Translational Advances, Nashville, Tennessee.
Xia LeiDepartment of Pharmacology, Vanderbilt University, Nashville, Tennessee; Warren Center for Neuroscience Drug Discovery and Vanderbilt Institute for Translational Advances, Nashville, Tennessee.
Xin LinDepartments of Psychiatry and Molecular Pharmacology and Therapeutics, Columbia University Vagelos College of Physicians and Surgeons, New York, New York; Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, New York.
Joseph D BungardDepartment of Pharmacology, Vanderbilt University, Nashville, Tennessee; Warren Center for Neuroscience Drug Discovery and Vanderbilt Institute for Translational Advances, Nashville, Tennessee.
Wesley B AsherDepartments of Psychiatry and Molecular Pharmacology and Therapeutics, Columbia University Vagelos College of Physicians and Surgeons, New York, New York; Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, New York.
Jonathan A JavitchDepartments of Psychiatry and Molecular Pharmacology and Therapeutics, Columbia University Vagelos College of Physicians and Surgeons, New York, New York; Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, New York.
Colleen M NiswenderDepartment of Pharmacology, Vanderbilt University, Nashville, Tennessee; Warren Center for Neuroscience Drug Discovery and Vanderbilt Institute for Translational Advances, Nashville, Tennessee; Vanderbilt Kennedy Center, Vanderbilt University Medical Center, Nashville, Tennessee; Vanderbilt Brain Institute, Vanderbilt University, Nashville, Tennessee; Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee. Electronic address: Colleen.niswender@vanderbilt.edu.

Funding

FUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTOR SUBTYPESR01NS031373 · NINDS · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 1993 to 2025
$6.2M
Development of mGlu7 receptor allosteric modulators for neurological and psychiatric disordersR01MH124671 · NIMH · VANDERBILT UNIVERSITY · PI LINDSLEY, CRAIG, NISWENDER, COLLEEN M · 2020 to 2024
$3.5M
Functions of Metabotropic Glutamate Receptor SubtypesR37NS031373 · NINDS · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 2014 to 2020
$3.5M
Impact of Metabotropic Glutamate Receptor Heteromerization on Signaling and PharmacologyR01NS132060 · NINDS · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI Jonathan A Javitch, COLLEEN M NISWENDER · 2023 to 2026
$2.4M
Identifying the molecular signatures of mGlu receptor heterodimersR21MH141461 · NIMH · VANDERBILT UNIVERSITY · PI NISWENDER, COLLEEN M · 2025 to 2025
$436k
NIMH NIH HHS R01 MH124671NIMH NIH HHS R21 MH141461NINDS NIH HHS R01 NS031373NINDS NIH HHS R01 NS132060NINDS NIH HHS R37 NS031373
6 · The paper itself

Abstract

The metabotropic glutamate (mGlu) receptors are family C G protein-coupled receptors that are widely expressed throughout the central nervous system and function as either homodimers or heterodimers. Recent literature suggests that specific mGlu heterodimer subtypes play critical functional roles in the brain and show unique pharmacological signatures relative to homodimers. We have previously shown that mGlu

Indexed as

Receptors, Metabotropic GlutamateAllosteric RegulationAnimalsHEK293 CellsHumansProtein Multimerizationmetabotropic glutamate receptor 7metabotropic glutamate receptor 8Receptors, Metabotropic GlutamateAllosteric modulatorsCentral nervous system disordersG protein–coupled receptorsmGlu

Identifiers

PMID42385300
PMCPMC13430957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.